At the Intersection of Science and Law
At the Intersection of Science and Law
Playlist by At the Intersection of Science and LawIn DLA Piper’s At the Intersection of Science and Law podcast, members of the firm’s Life Sciences team explore the connection between science and the law in areas that include AI and drug discovery, …Follow the podcast:
11 clip(s) in playlist
Cross-border considerations for privacy in clinical trials
Published in Chambers Expert Focus. With the recent publication of our Cross-border Guide to Clinical Trials and Privacy, James Clark, Paula Gonzalez de Castejón and David Kopans discuss ongoing and developing EU and US perspectives on privacy considerations with respect to cross-border clinical tr…
18:19
Global Life Sciences Supply Chain Insights
Published in Chambers Expert Focus. Lauren Murdza and Richard Taylor share their insights on supply chain issues in the life sciences sector in the latest episode of At the Intersection of Science and Law.
27:36
AI risk assessments: Future-proofing your innovation when rules can change mid-game
Published in Chambers Expert Focus. DLA Piper partner Danny Tobey is joined by Aviva Wein, Assistant General Counsel at Johnson & Johnson, to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise.
24:43
The rise of global telehealth
DLA Piper partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in technology aiming to address disparate access to healthcare globally.
25:34Clean
Advising the advisor: Tips for navigating the life sciences and regulatory environment
DLA Piper managing partner Emilio Ragosa is joined by Kevin Sheridan, Joint Global Head of Healthcare Investment Banking at Jefferies LLC, to discuss the importance of advisors having an understanding of the life sciences industry in order to provide value-added advice on transactions, including pu…
30:59Clean
The moral imperative: Balancing innovation, regulation and prescription drug availability
DLA Piper's Jim Greenwood and Geoff Levitt are joined by Peter Kolchinsky, founding Partner and Portfolio Manager at RA Capital, to discuss the importance of – and complications in – balancing biopharmaceutical innovation, industry regulations and prescription drug availability.
30:30Clean
Incentivizing diverse representation in clinical trials
Diverse representation in clinical trials is critical in achieving greater equity and better healthcare outcomes. DLA Piper's Kirsten Axelsen and Sarah Schick are joined by Shazia Ahmad, Senior Director and Head of Patient and Physician Services at UBC, to discuss the importance of regulatory incen…
22:40Clean
The crossroad of science and law
DLA Piper’s Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies.
26:16Clean
Social media’s impact on the life sciences industry
DLA Piper’s Chris Campbell and Jody Rhodes are joined by Sarah Heineman, Senior Assistant General Counsel at Bayer, to discuss how social media affects the public's view of medicine and science and how that in turn impacts the life sciences industry, including litigation.
34:50
Understanding AI and its use in drug discovery
DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.
31:48Clean